Can a Two-Pronged antibody boost chemo against tough lymphomas?
NCT ID NCT07724457
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This trial tests whether adding the bispecific antibody glofitamab to standard chemoimmunotherapy can improve outcomes for people with Burkitt lymphoma or high-grade B-cell lymphoma with MYC and BCL2 rearrangements. These are fast-growing cancers that can be hard to treat. The study enrolls patients whose disease is newly diagnosed, has returned, or has not responded to prior treatment. The goal is to see if the combination helps keep the cancer from progressing longer than standard therapy alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a bispecific antibody called glofitamab added to standard chemoimmunotherapy
- What this could lead to
- If successful, this could offer a more effective treatment option for aggressive B-cell lymphomas that are hard to treat.
- What could go wrong
- This is an early-to-mid-stage trial, so the added benefit of glofitamab is not yet proven. Side effects from the combination may be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT BURKITT LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gene therapy takes on HIV and cancer in one shot
- New drug cocktail aims to tackle tough blood cancers
- Promising lymphoma combo trial pulled before it began
- New Antibody-Drug combo aims to tackle tough leukemia
- New drug cocktail shows promise for Tough-to-Treat lymphoma
- Immunotherapy duo takes on tough lymphomas